Skip to content

Cranberry-lingonberry Juice Started During Acute Infection in Prevention of Urinary Tract Infections in Children

Randomized Controlled Trial of the Effect of Cranberry-lingonberry Juice on the Occurrence of Urinary Tract Infections, the Gut Microbiota, and the Uropathogenic Escherichia Coli

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01861353
Enrollment
113
Registered
2013-05-23
Start date
2013-05-31
Completion date
2019-02-28
Last updated
2022-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystitis, Pyelonephritis, Urinary Tract Infection

Brief summary

Cranberry and cranberry-lingonberry juice prevented urinary tract infections in children and in adults in our earlier clinical trials. The preventive effect was, however, observed late in the follow-up and the next recurrence was not prevented in children. The investigators hypothesize that cranberry-lingonberry juice should be started already during the antimicrobial treatment of acute urinary tract infection in order to maximize the preventive efficacy of the juice. In addition, the investigators aim to find the explanation for the efficacy of cranberry-lingonberry juice by analyzing the concomitant changes in the chemical composition of urine and feces as well as the changes of gut microbiota.

Interventions

OTHERCranberry-lingonberry juice
OTHERPlacebo juice

Juice iwth similar sugar concentration as cranberry-lingonberry juice but without berry extracts

Sponsors

University of Oulu
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Years to 16 Years
Healthy volunteers
No

Inclusion criteria

* Recent confirmed urinary tract infection, diagnosed in Oulu University Hospital or Oulu Health Care Center * Age 1-16 years

Exclusion criteria

* Continuous antimicrobial prophylaxis * Age \< 12 months or \> 16 years * Severe congenital kidney or other urinary tract anomaly in ultrasound

Design outcomes

Primary

MeasureTime frame
Change of the intestinal and urinary microbiome3 months to 12 months

Secondary

MeasureTime frame
The occurrence of urinary tract infections (infection episodes/person years at risk)12 months
Time to the first recurrence6 months

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026